TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis
Brief Summary: Previous work demonstrated that inhaled hypertonic saline (HS) reduces exacerbation frequency and improves lung function in adults with cystic fibrosis (CF). It is unclear, however, whether HS will benefit young patients suffering from CF. The investigators propose to further support the concept that HS can benefit children with mild CF lung disease by performing a relatively short, placebo controlled study of HS in 5-12 year olds, using lung function and mucociliary clearance as key outcome measures.


Options:
A: Arm Label: Master Study Run-in; Type: N/A; Interventions: N/A
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: Hypertonic saline; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic Saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hypertonic Saline; Assigned to Arm(s): Hypertonic saline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1
Brief Summary: This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in subjects with Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1). Subjects will apply either a Polyvinylidene fluoride (PVDF) coating (Skincerity) containing rapamycin or the PVDF coating alone nightly to fibromatous lesions for a duration of six months.

The primary goal of this study is to evaluate the safety of the topical product in patients with TSC and NF1. The secondary goal of this study is to evaluate the effectiveness of the topical product for treatment of cutaneous fibromatous lesions.


Options:
A: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Arm Label: NPC-12G gel; Type: EXPERIMENTAL; Interventions: Drug: NPC-12G gel | Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Intervention Type: DRUG; Name: NPC-12G gel; Assigned to Arm(s): NPC-12G gel | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): Placebo gel
D: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1
Brief Summary: This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in subjects with Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1). Subjects will apply either a Polyvinylidene fluoride (PVDF) coating (Skincerity) containing rapamycin or the PVDF coating alone nightly to fibromatous lesions for a duration of six months.

The primary goal of this study is to evaluate the safety of the topical product in patients with TSC and NF1. The secondary goal of this study is to evaluate the effectiveness of the topical product for treatment of cutaneous fibromatous lesions.


Options:
A: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
B: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A
C: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)
Brief Summary: Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI\>=15 or BDI\>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility criteria will be consented. Through informed consent, both arms of the trial will be described with equipoise as to these approaches to postACS depression care. Patients who consent to randomization will be enrolled in the treatment trial.

The intervention phase will be 6 months, and hence the final outcome assessments will be performed approximately 9 months after the index ACS. Interim measures of depression will be obtained at 2 and 4 months post-enrollment. Major adverse cardiac events and all-cause mortality will also be ascertained at 6 months post-enrollment. Quality assurance by an independent medical event adjudication committee using prospective guidelines will be employed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
B: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral interventional program | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral interventional program | Intervention Type: BEHAVIORAL; Name: Behavioral interventional program; Assigned to Arm(s): Behavioral intervention, Standard treatment
C: Arm Label: Referred Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy, Drug: Sertraline, citalopram, or bupropion | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Sertraline, citalopram, or bupropion; Assigned to Arm(s): Stepped Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Referred Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)
Brief Summary: Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI\>=15 or BDI\>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility criteria will be consented. Through informed consent, both arms of the trial will be described with equipoise as to these approaches to postACS depression care. Patients who consent to randomization will be enrolled in the treatment trial.

The intervention phase will be 6 months, and hence the final outcome assessments will be performed approximately 9 months after the index ACS. Interim measures of depression will be obtained at 2 and 4 months post-enrollment. Major adverse cardiac events and all-cause mortality will also be ascertained at 6 months post-enrollment. Quality assurance by an independent medical event adjudication committee using prospective guidelines will be employed.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Home-based Metacognitive Therapy (Home-MCT) | Intervention Type: OTHER; Name: Home-based Metacognitive Therapy (Home-MCT); Assigned to Arm(s): Intervention
B: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control
C: Arm Label: Referred Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy, Drug: Sertraline, citalopram, or bupropion | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Sertraline, citalopram, or bupropion; Assigned to Arm(s): Stepped Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Referred Care
D: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment
Brief Summary: To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a decrease in the average Ashworth Scale (AS) score in the lower extremities.


Options:
A: Arm Label: BACLOFEN; Type: EXPERIMENTAL; Interventions: Drug: BACLOFEN | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: BACLOFEN; Assigned to Arm(s): BACLOFEN | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO
B: Arm Label: ITB therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: intrathecal baclofen | Arm Label: Best Medical Treatment (BMT); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: intrathecal baclofen; Assigned to Arm(s): ITB therapy
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 30mg/day | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 75mg/day | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen 30mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Baclofen 75mg/day; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Baclofen | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Falls in Community-dwelling Older Adults by a Standardized Assessment of Fall Risks in the General Practitioner Setting and Through Implementation of a Network for Effective Individual Reduction on Fall Risks.
Brief Summary: The primary aim of this two-year project for falls prevention is to reduce number of falls and fall incidence in community-dwelling people of 65 years and older in the setting of general practitioners. In addition a reduction of fall-related injuries, reduction of fall-related risk factors and preservation of Quality of Life is to be achieved.

A second goal of this study is the implementation of standardized assessment for fall risk factors as well as building up a network between instructors for fall prevention exercise and general practitioners.


Options:
A: Arm Label: Cognitive Behavioral Therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive, CBT-based, multi-component treatment | Arm Label: Treatment as usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Comprehensive, CBT-based, multi-component treatment; Assigned to Arm(s): Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual (TAU)
B: Arm Label: DESTRESS-WV; Type: EXPERIMENTAL; Interventions: Behavioral: DESTRESS-WV | Arm Label: Phone Monitoring; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Phone Monitoring | Intervention Type: BEHAVIORAL; Name: DESTRESS-WV; Assigned to Arm(s): DESTRESS-WV | Intervention Type: BEHAVIORAL; Name: Phone Monitoring; Assigned to Arm(s): Phone Monitoring
C: Arm Label: observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise intervention | Intervention Type: OTHER; Name: Exercise intervention; Assigned to Arm(s): Exercise group
D: Arm Label: DESTRESS-PC; Type: EXPERIMENTAL; Interventions: Behavioral: DESTRESS-PC | Arm Label: OUC; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized Usual Primary Care PTSD treatment | Intervention Type: BEHAVIORAL; Name: DESTRESS-PC; Assigned to Arm(s): DESTRESS-PC | Intervention Type: OTHER; Name: Optimized Usual Primary Care PTSD treatment; Assigned to Arm(s): OUC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Falls in Community-dwelling Older Adults by a Standardized Assessment of Fall Risks in the General Practitioner Setting and Through Implementation of a Network for Effective Individual Reduction on Fall Risks.
Brief Summary: The primary aim of this two-year project for falls prevention is to reduce number of falls and fall incidence in community-dwelling people of 65 years and older in the setting of general practitioners. In addition a reduction of fall-related injuries, reduction of fall-related risk factors and preservation of Quality of Life is to be achieved.

A second goal of this study is the implementation of standardized assessment for fall risk factors as well as building up a network between instructors for fall prevention exercise and general practitioners.


Options:
A: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Multifactorial Falls Prevention Program; Type: EXPERIMENTAL; Interventions: Other: On-site exercise, Other: home-based exercise, Other: Educational and behavioural, Other: Management of modifiable risk factors | Intervention Type: OTHER; Name: On-site exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: home-based exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Educational and behavioural; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Management of modifiable risk factors; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: physical therapy | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: physical therapy; Assigned to Arm(s): Intervention Group
D: Arm Label: observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise intervention | Intervention Type: OTHER; Name: Exercise intervention; Assigned to Arm(s): Exercise group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
B: Arm Label: bevacizumab and erlotinib (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, erlotinib | Arm Label: bevacizumab (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: bevacizumab (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: low dose capecitabine (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: low dose capecitabine | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): bevacizumab and erlotinib (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS mutated) | Intervention Type: DRUG; Name: low dose capecitabine; Assigned to Arm(s): low dose capecitabine (KRAS mutated)
C: Arm Label: lenalidomide plus cetuximab; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, Drug: lenalidomide | Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): lenalidomide plus cetuximab | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide, lenalidomide plus cetuximab
D: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru
Brief Summary: The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).


Options:
A: Arm Label: 1.1; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine. | Arm Label: 1.2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate. | Arm Label: 2.1; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine. | Arm Label: 2.2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate. | Intervention Type: DRUG; Name: Miltefosine.; Assigned to Arm(s): 1.1 | Intervention Type: DRUG; Name: Meglumine antimoniate.; Assigned to Arm(s): 1.2 | Intervention Type: DRUG; Name: Miltefosine.; Assigned to Arm(s): 2.1 | Intervention Type: DRUG; Name: Meglumine antimoniate.; Assigned to Arm(s): 2.2
B: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
C: Arm Label: Miltefosine; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine | Arm Label: Glucantime®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucantime® | Arm Label: Thermotherapy; Type: EXPERIMENTAL; Interventions: Device: Thermotherapy | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Miltefosine | Intervention Type: DEVICE; Name: Thermotherapy; Assigned to Arm(s): Thermotherapy | Intervention Type: DRUG; Name: Glucantime®; Assigned to Arm(s): Glucantime®
D: Arm Label: Single dose of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Single dose of Pentamidine | Arm Label: Two doses of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Two doses of Pentamidine | Arm Label: Three doses of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Three doses of Pentamidine | Intervention Type: DRUG; Name: Single dose of Pentamidine; Assigned to Arm(s): Single dose of Pentamidine | Intervention Type: DRUG; Name: Two doses of Pentamidine; Assigned to Arm(s): Two doses of Pentamidine | Intervention Type: DRUG; Name: Three doses of Pentamidine; Assigned to Arm(s): Three doses of Pentamidine

Answer: B